These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27993663)

  • 21. A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
    Kratiras Z; Konstantinidis C; Skriapas K
    Int Braz J Urol; 2014; 40(1):3-15; discussion 15. PubMed ID: 24642162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent androgen deprivation.
    Dawson NA
    Curr Oncol Rep; 2000 Sep; 2(5):409-16. PubMed ID: 11122872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.
    Botrel TE; Clark O; dos Reis RB; Pompeo AC; Ferreira U; Sadi MV; Bretas FF
    BMC Urol; 2014 Jan; 14():9. PubMed ID: 24460605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
    Klotz L; Loblaw A; Siemens R; Ouellette P; Kapoor A; Kebabdjian M; Zhang L; Saad F;
    J Urol; 2018 Aug; 200(2):335-343. PubMed ID: 29534997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Intermittent and Continuous Androgen Deprivation Therapy in Prostate Cancer Patients: An Up-to-Date Meta-analysis for Urologists and Medical Providers.
    Becker B; Stroever S; Reddy A; de Riese WTW
    Urol Pract; 2023 Sep; 10(5):424-434. PubMed ID: 37505912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer.
    Klotz L
    Curr Urol Rep; 2013 Jun; 14(3):159-67. PubMed ID: 23700095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
    Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
    Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer.
    Hicks BM; Klil-Drori AJ; Yin H; Campeau L; Azoulay L
    Epidemiology; 2017 Sep; 28(5):712-718. PubMed ID: 28768300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group.
    Calais da Silva F; Bono A; Whelan P; Brausi M; Queimadelos M; Portillo J; Kirkali Z; Robertson C
    Oncology; 2003; 65 Suppl 1():24-8. PubMed ID: 12949430
    [No Abstract]   [Full Text] [Related]  

  • 31. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
    J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong.
    Teoh JY; Chiu PK; Chan SY; Poon DM; Cheung HY; Hou SS; Ng CF
    Jpn J Clin Oncol; 2015 May; 45(5):483-7. PubMed ID: 25724216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 37. A Prospective Audit of Intermittent Anti-Androgen verses Pituitary Blockade Suggests a Bipolar Androgen Type Strategy May Be Safe in Untreated Prostate Cancer.
    Oliver T; Wilson P; Ansell W; Philp T; Chinegwundoh F; Shamash J; Shaw G; Ahmad A
    Urol Int; 2018; 100(2):172-180. PubMed ID: 29275414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
    Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
    Keating NL; O'Malley AJ; Freedland SJ; Smith MR
    Eur Urol; 2013 Jul; 64(1):159-66. PubMed ID: 22537796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
    de Leval J; Boca P; Yousef E; Nicolas H; Jeukenne M; Seidel L; Bouffioux C; Coppens L; Bonnet P; Andrianne R; Wlatregny D
    Clin Prostate Cancer; 2002 Dec; 1(3):163-71. PubMed ID: 15046691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.